Cargando…

The Osteosarcoma Stem Cell Activity of a Gallium(III)‐Phenanthroline Complex Appended to Salicylate

We report the synthesis, characterisation, and anti‐osteosarcoma properties of a gallium(III) complex (1) comprising of two 1,10‐phenanthroline ligands and salicylate, a non‐steroidal anti‐inflammatory drug. The gallium(III) complex 1 displays micromolar potency towards bulk osteosarcoma cells and o...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincent, Ruby A., Passeri, Ginevra, Northcote‐Smith, Joshua, Singh, Kuldip, Suntharalingam, Kogularamanan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099568/
https://www.ncbi.nlm.nih.gov/pubmed/36281941
http://dx.doi.org/10.1002/cbic.202200532
Descripción
Sumario:We report the synthesis, characterisation, and anti‐osteosarcoma properties of a gallium(III) complex (1) comprising of two 1,10‐phenanthroline ligands and salicylate, a non‐steroidal anti‐inflammatory drug. The gallium(III) complex 1 displays micromolar potency towards bulk osteosarcoma cells and osteosarcoma stem cells (OSCs). Notably, the gallium(III) complex 1 exhibits significantly higher toxicity towards OSCs grown in monolayer and three‐dimensional cultures than cisplatin, a frontline anti‐osteosarcoma drug. Nuclei isolation and immunoblotting studies show that the gallium(III) complex 1 enters osteosarcoma cell nuclei and induces DNA damage. Flow cytometry and cytotoxicity studies (in the presence of prostaglandin E2) indicate that the gallium(III) complex 1 downregulates cyclooxygenase‐2 (COX‐2) expression and kills osteosarcoma cells in a COX‐2‐dependent manner. Further, the mode of osteosarcoma cell death evoked by the gallium(III) complex 1 is characterised as caspase‐dependent apoptosis.